Our team is currently evaluating the combination of the immune checkpoint blockade in a neoadjuvant or adjuvant setting with IL13Rα2-CAR T therapy for the treatment of recurrent GBM patients (NCT04003649). Here, IL13RA2 is linked to glioblastoma.